drugset / Trial / NCT04826016
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter Phase Ib/II, open-label, dose-escalation study to optimize POL6326 (balixafortide) in combination with nab-paclitaxel or eribulin in patients with HER2-negative advanced breast cancer.
Timeline
- Start
- 2022-03-16
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balixafortide | Peptide | 5.5 mg/kg | Intravenous |
| Subject | Balixafortide | Peptide | 11 mg/kg | Intravenous |
| Background | Eribulin | Small molecule | 1.23 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |